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hypoglycemia associated with mu-
tations in hypoxia upregulated 1To the Editor:
Immunodeficiencies featuring congenital neutropenia have
varying presentations, including life-threatening bacterial in-
fections. These conditions can be caused by defects in more
than 10 genes.1-3 Most genes operate in the endolysosomal sys-
tem, and their perturbed action induces unfolded protein response
and altered mitochondrial function. The resulting cell stress
drives neutrophils to apoptosis.1-3
We evaluated a 45-year-old woman showing symptoms of
combined immunodeficiency and disturbed glucose metabolism
since birth (for detailed case description, see this article’s Online
Repository at www.jacionline.org). She was born small for gesta-
tional age and her subsequent growth was poor. Her appearance
was slightly dysmorphic, featuring oval face, pectus carinatum,
and broad long bone metaphyses. During childhood, she experi-
enced episodes of stress-induced hypoglycemia. From infancy to
adulthood, she suffered from numerous septic infections of the res-
piratory tract, skin, and mucous membranes. At age 4 years, she
had severe septic herpetic gingivostomatitis, after which herpetic
stomatitis recurred monthly for several years. In adulthood, she
contracted herpetic encephalitis followed by recurring condyloma-
tous warts in her thighs and genital area. G-CSF and intravenous
immunoglobulin treatment were initiated in her 20s, which led to
the normalization of her absolute neutrophil count and significantly
decreased the rate of bacterial infections. An immunodysregula-
tory component was evident, as the patient developed hidradenitis
suppurativa in her teens and relapsing Takayasu arteritis as an
adult. Currently, the patient receives G-CSF, immunoglobulin
replacement therapy, rituximab, and oral prednisolone (5 mg/d).
Detailed immunological workup is presented in Tables E1-E3
in this article’s Online Repository at www.jacionline.org. The pa-
tient showed broad abnormalities in the myeloid lineage. She had
microcytic anemia, fluctuating thrombocytopenia, and constant
granulocytopenia (see Table E1 in this article’s Online
Repository at www.jacionline.org). Neutrophils showed poor
chemotaxis and increased activation. Bone marrow biopsies
showed inconstant myeloid maturation arrest that resolved on
G-GSF treatment (data not shown).
In addition, antigen presentation and adaptive immunity were
affected. Both plasmacytoid and monocytoid dendritic cells were
reduced in peripheral blood, and the expression of costimulatory
CD86 molecule was low in both monocytoid dendritic cells and
monocytes. These together with a low PHA stimulation response
suggested impaired antigen presentation. In the T-cell compart-
ment, the proportions of CD41 and CD81 T cells were within
normal range, with naive CCR71CD45RA1 cells dominating
the repertoire. The B- cell count was very low, and B-cell devel-
opment skewed toward mature B cells with reduced switched
memory B cells. Despite normal immunoglobulin levels, re-
sponses to polysaccharide antigens were completely absent. It
is unlikely that the observed changes are due to the patient’s 2016 The Authors. Published by Elsevier, Inc. on behalf of the American Academy of
Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).immunosuppressive regimen because most studies were carried
either without or with low-dose immunosuppression (predniso-
lone 5 mg/d).
Because of a suspected novel primary immunodeficiency, we
performed whole-exome sequencing. We identified novel com-
pound heterozygous missense mutations in the hypoxia upregu-
lated 1 (HYOU1) gene (Fig 1, A; also see Fig E1 in this article’s
Online Repository at www.jacionline.org).4,5 The mutations
(chr11: 118922614 C>G, p.A419P and chr11:118924936 A>G,
p.Y231H) localized to the ATPase domain of HYOU1, negatively
affecting conserved residues. HYOU1 is a chaperone that
localizes to endoplasmic reticulum (ER) and mitochondria, and
participates in cell stress responses, including oxidative stress
and unfolded protein response.4,6,7 Because most genes that
cause congenital neutropenia perform similar functions,
HYOU1 was considered a good candidate (for detailed
comparison, see Table E4 in this article’s Online Repository at
www.jacionline.org). HYOU1 further belongs to herpes
infection-induced proteome.8
We hypothesized that mutations in HYOU1 ATPase domain
would impair ATP hydrolysis, thereby hampering the conforma-
tional changes required for HYOU1 chaperone function.4,5
Consequently, this could lead to altered substrate binding.
To test this, we performed affinity-purification mass spectrometry
(AP-MS) on Strep-tagged wild type (WT) and mutant
(MT) HYOU1 proteins expressed in tetracycline-inducible
HEK293 cell lines. Both mutants bound with high affinity to a
range of proteins that did not bind to WT HYOU1 (Fig 1, C).
Thus, the binding profiles of themutatedHYOU1 proteins seemed
altered, leading to ectopic protein binding.
To measure ER stress, we performed RNA sequencing on
patient and control primary skin fibroblasts with and without
tunicamycin, a compound that induces unfolded protein response
(Fig 1, B; see Fig E2 in this article’s Online Repository at www.
jacionline.org). Compared with normal controls, the transcrip-
tional profile was strikingly different in patient cells, and tran-
scripts from ectopic Y231H and A419P interaction partners
were upregulated. In steady state, the transcriptome suggested
enhanced protein synthesis, glucose metabolism, and redox
enzyme transcription in patient cells. Interestingly, a clear enrich-
ment in redox proteins was also noted among HYOU1-binding
partners in AP-MS (Fig 1, C).
As results fromRNA sequencing and AP-MS pointed to altered
cell metabolism, we performed mass spectrometry–based tar-
geted analysis of 100metabolites in patient and control fibroblasts
(see Fig E3 in this article’s Online Repository at www.jacionline.
org). Again, we noted altered quantities of metabolites in path-
ways participating in redox balance.
To further characterize the phenotype, we studied patient and
healthy control neutrophils with electron microscopy. The ER
morphology was normal. However, we noted increased numbers
of mitochondria along with high reactive oxygen species produc-
tion in patient neutrophils (Fig 1, D and E, and see Table E1). To
see whether the increased mitochondrial quantity and altered
redox balancewere caused by defectivemitochondrial respiration,
we performedXFCellMito Stress test on patient and healthy con-
trol fibroblasts (see Fig E3 in this article’s Online Repository at
www.jacionline.org). The patient fibroblasts performed consis-
tently on low normal scale; significant alterations, however,
were not evident.
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FIG 1. A, HYOU1 structure4 with the observed mutations. B, RNA expression profile in primary fibroblasts. C,
Interaction partners ofWT andmutant HYOU1 proteins as determined by affinity-purificationmass-spectrom-
etry (AP-MS). Black line denotes mitochondrial proteins. D and E, Electron micrograph figures of control (left)
and patient (right) neutrophils show abundant mitochondria. F, Comparison of enriched pathways between
RNA sequencing, AP-MS (denoted as binding assay), and targeted metabolite profiling (referred as metabolic
assay). Poly-Phen, PolymorphismPhenotyping (algorithm);SIFT, Sorting Intolerant fromTolerant (algorithm).
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response and mitochondrial function were altered in the index
case. The findings were consistent with previous knowledge on
HYOU1 function, and strengthened the causative role of the
mutations.
In conclusion, we describe a novel immunometabolic syn-
drome caused by recessiveHYOU1mutations. The condition fea-
tures hypoglycemia and severe bacterial and herpetic infections.
Immunologically, granulocytopenia and B-cell and dendritic
cell deficiency are evident. G-CSF treatment is effective incorrecting neutropenia and with intravenous immunoglobulin re-
duces the rate of infections. Our results are in line with previous
reports linking members of the endolysosomal system to congen-
ital neutropenia, and suggest that perturbed redox balance plays a
role in these conditions.
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decreases IgE to Ara h 2 and
Ara h 6 but does not enhance
sensitization to cross-reactive
allergensTo the Editor:
Oral immunotherapy (OIT) induces specific IgG4 antibodies
and regulatory T cells and leads to suppression of IgE-mediated
reactions.1 In pollen immunotherapy, specific IgE levels to pollen
allergens decrease with increasing IgG4.
2,3 We aimed to study
whether peanut OIT would induce neosensitization or affect
cross-reactive proteins by analyzing IgE sensitization profiles
using microarrays. In addition, we analyzed IgG4-IgE ratios to
peanut allergens during OITand assessed whether the cumulative
protein dose ingested during treatment determines the changes in
IgG4/IgE.
Fifty-eight 6- to 18-year-old children and adolescents having
moderate-to-severe peanut allergy participated in the study. The
diagnosis was based on a double-blind placebo-controlled
peanut challenge (n 5 52) or serum IgE to Ara h 2 above 25 kU/
L (27.8-365 kU/L) (n 5 6). Thirty-nine patients received peanut
OIT, whereas 19 patients continued to avoid peanuts. During
8 months, the daily peanut protein intake increased from 0.1 to
800 mg, after which patients ingested 4 peanuts daily. During the
first 19 build-up weeks, the patients used roasted defatted peanut
flour (Byrd Mill, Ashland, Va), which showed 100% allergen
activity of Ara h 1, 2, 3, and 6, 30% of Ara h 8, but lack of (<20%)
Ara h 9 activity in Immuno Solid-phase Allergen Chip
(ImmunoCAP ISAC, Thermo Fisher Scientific, Uppsala, Sweden)
inhibition assay.4 From week 20 on, the patients consumed
whole peanuts. Serum samples were drawn at baseline and after
build-up.
We measured serum IgE to 112 allergen components using the
ISAC with a detection limit of 0.3 ISAC standardized units for
specific IgE (ISU-E). We measured IgE to hazelnut Cor a 14
and cashew Ana o 3, and IgE and IgG4 to whole peanut extract,
Ara h 1, 2, 3, 8, and 9, using ImmunoCAP (Thermo Fisher
Scientific). IgE and IgG4 to Ara h 6 were measured using an
experimental ImmunoCAP test. Sensitization was defined as
>_0.3 ISU-E. The ethics committee at the Helsinki University
Hospital approved the study protocol. Patients and 1 of their
parents provided informed written consent. Data analysis
protocols can be found in the Online Repository (available at
www.jacionline.org).
At baseline, all 58 patients were sensitized to Ara h 2 (97%)
and/or Ara h 6 (98%). In addition, the majority was sensitized to
Ara h 1 (74%), Ara h 3 (70%), or Ara h 8 (79%), but only 9%were
sensitized to Ara h 9. Sensitization to any Ara h 8–cross-reactive
pathogenesis-related proteins group 10 (PR-10) protein occurred
CASE DESCRIPTION
The patient is a 41-year old woman born to nonconsangui-
neous parents after uneventful pregnancy. Family history is
negative for major illnesses. She was born small for gestational
age (2270 g/41 cm) at week 3614. After birth, she developed
hyperbilirubinemia and hypoglycemia, necessitating photother-
apy and intravenous glucose administration. Some days later,
she suffered from postpartum omphalitis caused by Entero-
coccus faecalis and was treated with intravenous antibiotics.
Hypoglycemia, often precipitated by infection, recurred
throughout childhood. Tested later, her insulin and glucagon
levels were normal (10.5 mU/L and 164 ng/L, respectively); pe-
diatric values were unavailable.
Her growth alternated between –2.5 and –3.2 SD, and end
height became 152 cm (22.9 SD) with an arm span of
154.5 cm. Her long bone metaphyses were abnormally broad
on repeated X-ray examinations. Bone age was somewhat
delayed until puberty. Although moderate learning problems
were noted at school, her cognitive functions are normal. Her
physical appearance is slightly dysmorphic, with somewhat
narrow and oval face, high-sloped forehead, high hairline, low
normal earlobes, broad nasal bridge, prominent narrow nose,
micrognathia, high palate, mild pectus carinatum, and long
slender fingers with narrow long nails. Her menarche was
somewhat delayed (age 15 years).
At age 2 years, her thymus appeared hypoplastic in chest X-ray.
After uncomplicated BCG vaccination, PPD test result became
positive at 100 TU. Severe granulocytopenia with normal mono-
cyte levels was noted at age 3 years, and antigranulocyte
antibodies were negative. From early infancy to adulthood, she
has suffered from numerous purulent infections in upper and
lower respiratory tract, skin, and mucous membranes. These
necessitated hospital admissions 5 to 6 times per year. The
infections frequently became septic and required intravenous
antibiotic treatment as well as repeated abscess drainages,
tympanostomies, myringoplasties, and repetitive grommet place-
ments, even in adulthood. Functional endoscopic sinus surgery
was performed at age 28 years to alleviate purulent sinusitis.
Common encapsulated pathogens (S pneumoniae, S aureus, S
pyogenes, S viridans) were cultured from infections. At school
age, she suffered from relapsing suppurative hidradenitis of the
left axillar fossa that spontaneously disappeared in her late teens.
Recurrent aphthous stomatitis was diagnosed at an early age.
At age 4 years, she also developed septic herpetic gingivostoma-
titis requiring intensive care. Herpetic stomatitis then recurred
monthly for years. In adulthood, she suffered an episode of
herpetic encephalitis. These subsequently lead to long-term
valaciclovir prophylaxis. She was started on G-CSF and subcu-
taneous immunoglobulin replacement therapy in her 20s. These
significantly decreased the rate of bacterial and viral infections.
In infancy and at preschool age, the patient also suffered from
constant diarrhea and malabsorption, which later corrected
spontaneously. No clear evidence for pancreatic insufficiency
was noted; however, the level of serum amylase had repeatedly
been below reference. Hepatomegaly with elevated alkaline
phosphatase and activated partial thromboplastin time was first
diagnosed at age 4 years after granulocyte transfusion during a
septic episode and disappeared by the age of 9 years. At age
29 years, she again developed hepatomegaly with spontaneous
resolution in subsequent years.
In her late 20s, she underwent several spontaneous miscar-
riages, mostly because of placental bleeding. Two of the
pregnancies resulted in placental thrombosis and microabscesses,
septic infection, and fetus mortus at week 20 to 22. Lupus
anticoagulant and autoantibodies to phospholipase A2 receptor
were positive.
At age 43 years, the patient developed acute high fever and chest
pain. No signs of specific infections were found and she did not
respond to broad-spectrum antibiotics. Based on computed tomog-
raphy findings, Takayasu arteritis was diagnosed, with a favorable
response tocorticosteroid treatment.Shehas continuedbeing active
and is able to work despite frequent episodes of severe illnesses.
In addition to granulocytopenia and dendritic and B-cell
deficiency, the patient has constant microcytic, hypochromic
anemia (mean corpuscular volume 65) with normal serum iron
indices. In addition, mild thrombocytopenia was present in
childhood. As an adult, episodes of thrombocytopenia have
been noted during infections. Bone marrow examinations occa-
sionally but inconstantly showed both megakaryocytes with
fragmented nucleoli and myeloid maturation arrest that resolved
on G-CSF treatment. No signs of malignant transformation have
been noted in repeated bone marrow examinations.
METHODS
Study participants
The study was conducted in accordance with principles of the Declaration
of Helsinki and was approved by the Helsinki University Central Hospital
Ethics Committee. Written informed consent was obtained from the patient
and healthy controls.
DNA extraction and whole-exome sequencing
GenomicDNAwas extracted fromEDTA-blood samples or salivary samples
using Qiagen FlexiGene DNA kit (Qiagen, Hilden, Germany) or OraGene
DNA Self-Collection Kit (OGR-250, DNA Genonek). Libraries were
processed according to Agilent SureSelect Target Enrichment System (Agilent
Technologies, Santa Clara, Calif) for Illumina Paired-End Sequencing Library
(Illumina, San Diego, Calif) using SureSelect Human All Exon V5 capture
library (Agilent Technologies). Libraries were sequenced with 101 bp read
length (HiSeq1500 sequencing platform, Illumina).
The read mapping, variant calling, and genome annotation were performed
as described previously.E1 On the basis of severe phenotype and the fact that
the parents were asymptomatic, we hypothesized the condition to be caused by
a mutation negatively affecting the coding sequence. We suspected the muta-
tion to be either a de novo dominant change in the amino acid sequence or a
homozygous or compound heterozygous recessive variant.
To find dominant variants, we filtered the data for coding mutations not
present in control databases (The Exome Aggregation Consortium Browser,
1000 Genomes, NHLBI Exome variant server, and UK TWINALSPAC study
cohorts as well as in-house databases). The remaining variants that showed
phylogenetic conservation or were predicted damaging by bioinformatics
tools (SIFT, Poly-Phen) were screened from the asymptomatic parents by
Sanger sequencing. Because all these were present in at least 1 parent, we
concluded that a de novo coding variant was unlikely to cause the disease.
For recessive variants, we filtered the data for rare homozygous or
compound heterozygous coding variants (MAF< 0.001 in the aforementioned
healthy control data sets). We identified recessive coding mutations in 10
genes. Only the compound heterozygous mutations in HYOU1 gene were
damaging and showed phylogenetic conservation. The candidate mutations
were verified by capillary sequencing from blood DNA samples.
B- and T-cell immunophenotyping
Fresh EDTA-blood samples or PBMCs were used for B- and T-lymphocyte
immunophenotyping, using 4- or 6-color flow cytometry panel with mAbs
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against the surface antigens IgM, IgD, CD3, CD4, CD8, CD16⁄56, CD19,
CD21, CD27, CD33, CD34, CD38, CD45, CD56, CD57, CD133, HLA-DR,
CD62L, CD45RA, and CD45RO (BD Biosciences). The memory status of
T cells was studied with the antibody panel including anti-CD45, anti-CD3,
anti-CD4, anti-CD45RA, and anti-CCR7 (R&D Systems, Minneapolis,
Minn).E1
Evaluation of T-cell responses is described in detail elsewhere.E1 For the
assessment of T-cell activation, fresh mononuclear cells were stimulated for
6 hours with anti-CD3, anti-CD28, and anti-CD49d (BD Biosciences). The
cells were analyzed using a 4- or 6-color flow cytometry panel with mAbs
against the antigens CD45, CD3, CD4, CD8, CD16, CD56, CD45,
CD45RA, TCR-g, CCR7, IFN-g, and TNF.
Phenotyping of TH17 and regulatory T cells
Phenotyping of IL-17–positive TH17 cells and regulatory T (Treg) cells is
described in detail elsewhere.E1 To assess IL17 expression, fresh PBMNCs
were stimulated for 16 hours with anti-CD3/anti-CD28 beads in the presence
of Brefeldin A. Thereafter, the cells were fixed, permeabilized, and stained
with anti-CD4, anti-CD69, and IL-17A (BD Biosciences) and analyzed with
FACSAria II or FACSCanto II flow cytometer.
Treg cells were immunophenotyped from fresh blood with surface markers
against CD4, CD25, and FOXP3 (BD Biosciences). For evaluation of Treg-
cell suppressor capacity, CD41CD251CD1272 Treg cells were sorted from
whole blood using Human CD41 T-Cell Enrichment Cocktail (Stemcell
Technologies, Vancouver, British Columbia, Canada) and fluorescence-
activated cell sorting with mAbs against CD4, CD25, and CD127 (BD
Biosciences). The cells were incubated for 6 days with carboxyfluorescein
succinimidyl ester (CFSE)-labeled autologous responder T cells in a ratio of
1:2. Anti-CD3/anti-CD28 beads (Life Technologies) were used as stimulus.
CD41 cells were analyzed using FACSAria II flow cytometer (BD Biosci-
ences). The suppression percentage was calculated with the following for-
mula: 100 2 [(% proliferation in presence of Treg cells/% proliferation in
absence of Treg cells) 3 100].
Monocyte and dendritic cell activation assays
For detailed immunophenotyping of monocytes and dendritic cells,
immediately after collection, heparinized blood samples from the patient
and 3 healthy controls were incubated in the presence of 100 ng/mL Escher-
ichia coli LPS, 25 mg/mL polyinosinic-polycytidylic acid, or vehicle for
1 hour.
Stimulated samples were then mixed with surface marker antibodies
(BDCA2 [Miltenyi Germany], CD1c [Miltenyi], CD14 [Invitrogen], CD19
[Invitrogen], CD80 [Becton Dickinson, Franklin Lakes, NJ], CD86 [Becton
Dickinson], a4 [Serotec, Hercules, Calif], b7 [Becton Dickinson], CCR9
[R&D Systems], and CCR2 [R&D Systems]) or an equal concentration of
their corresponding isotype controls and incubated for 20 minutes in the dark
at room temperature. The red blood cells were then lysed by incubating the
whole blood in 2 mL of FACS Lysing Solution (Becton Dickenson) for
10 minutes. The white blood cells were then pelleted out of solution by
centrifugation (500g for 5 minutes, room temperature) and washed twice with
a washing solution of 5% inactivated FCS (sterile, 0.22 mm filtered), 0.02%
NaN3, and PBS. The washed cells were then fixed with 1% paraformaldehyde
in PBS and stored overnight in the dark at148C. Staining controls for fluores-
cence compensation were prepared using 1 test volume of each specific anti-
body bound toOneCompBeads (eBiosceinces, Frankfurt, Germany). The data
were analyzed with FACSCalibur flow cytometer (BD Biosciences).
Neutrophil functional studies
Neutrophil C5a and formyl-methionyl-leucyl-phenylalanine–induced
chemotaxis was assessed according to standard clinical procedures. Neutro-
phil chemiluminescence test was performed according to standard protocols to
assess reactive oxygen species generation.
To evaluate neutrophil activation, fresh blood was stimulated with 100 ng/
mL E coli LPS for 1 hour, stained with surface marker antibodies (CD66b
[Biolegend], CD14 [Invitrogen], CD66a [Diaclone], and CD11b [BD Biosci-
ences]), as described above.
Fibroblast cultures and generation of inducible
Flp-In 293 T-REx cell lines
Fresh skin biopsies were cut into small pieces and transferred to 12-well
plates containing RPMI medium supplemented with 20% FBS, 1% L-gluta-
mine, and 1% penicillin-streptomycin. The cells were grown for 2 to 3 weeks,
then split onto 10-cm petri dishes, and frozen for later use when 80%
confluent.
The cDNA constructs containing WT, p.Y231H, and p.A419P mutant
HYOU1 full-length coding sequences were commercially cloned into gateway
compatible entry-vector (GenScript) and finally to pTO_HA_Stre-
pIII_c_GW_FRT destination vector. Flp-In 293 T-Rex cells were transfected
and cultured according to manufacturer’s instructions (Life Technologies).
The stable expression of mutant and WT Twin-Strep-tag HYOU1 upon tetra-
cycline induction was confirmed by Western blotting and immunofluores-
cence microscopy (see Fig E1).
Western blotting and immunofluorescence
microscopy
For Western blotting analysis, 53 105 Flp-In 293 T-Rex cells were seeded
to 6-well plates, induced with tetracycline, harvested to Laemmli Sample
Buffer, boiled, and ran to SDS-PAGE gel. Proteins were transferred onto nitro-
cellulose membrane and detected with anti-hemagglutin (HA) primary (HA-
11, Covance) and horseradish peroxidase–conjugated secondary antibody.
Signal was visualized by chemiluminescence. For immunofluorescent stain-
ing, cells were seeded onto coverslips, induced with tetracycline, fixed with
4% paraformaldehyde (PFA), and stained with anti-HA antibody and Alexa-
488 goat antimouse IgG (Life Technologies, Thermo Fisher Scientific, Wal-
tham, Mass). Nuclei were visualized with 49-6-diamidino-2-phenylindole, di-
hydrochloride staining before mounting with Mowiol (Sigma, St Louis, Mo).
Affinity purification and mass spectrometry
Approximately 5 3 107 cells were lysed in HNN lysis buffer (50 mM
HEPES, pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 50 mM NaF,
1.5 mMNa3VO4, 1.0 mM phenylmethylsulfonyl fluoride, and 10mL/mL pro-
tease inhibitor cocktail; Sigma). The proteins were bound using Strep-Tagtin
sepharose and Bio-Spin chromatography column (Bio-Rad) and eluted with
D-biotin (Thermo Scientific). Each sample was analyzed in quadruplicates:
2 biological replicates were analyzed in 2 technical replicates.
Mass spectrometry analyses were performed on an Orbitrap Elite ETD
mass spectrometer (Thermo Scientific). Peak extraction and subsequent
protein identification was achieved using Proteome Discoverer software
(version 1.4.1.14, Thermo Scientific). Calibrated peak files were searched
against the human component of UniProtKB/SwissProt database (www.
uniprot.org) by a SEQUEST search engine. Error tolerances on the precursor
and fragment ions were 615 ppm and 60.8 Da, respectively. Database
searches were limited to fully-tryptic peptides with maximum 1missed cleav-
age; carbamidomethyl cysteine andmethionine oxidationwere set as fixed and
variable modifications, respectively. The biological clustering and pathway
analysis was conducted using DAVID bioinformatics database (https://
david.ncifcrf.gov).
Metabolomics profiling by mass spectrometry
Primary cultured skin fibroblasts from patient and 2 healthy controls were
plated on 6-well plates and grown to 80% to 90% confluency. The cells were
then trypsinised, washed twice with PBS, and then with deionized water for
few seconds. Each cell line was analyzed in triplicate.
Approximately 106 cells per sample were taken for metabolomics analysis.
Metabolites were extracted by adding 20 mL of labeled internal standard mix
and 1 mL of cold extraction solvent (80/20 acetonitrile/H2O 1 1% formic
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acid). Cells were then sonicated for 30 seconds, vortexed for 30 seconds, and
incubated on ice for 10 minutes. After the centrifugation, supernatants were
aspirated into eppendorf tubes. Metabolites were separated usingWaters Acq-
uity ultra performance liquid chromatography and analyzed by triple quadru-
pole mass spectrometry. One hundred metabolites from 16 different
metabolite classes were analyzed. A detailed list of analyzed metabolites is
available at https://www.fimm.fi/en/services/technology-centre/metabolo
mics/metabolomics-services . The enriched metabolic pathways were evalu-
ated using quantitative enrichment analysis (http://www.metaboanalyst.ca).
Granulocyte isolation and electron microscopy
Plasmawas separated from the blood cell fraction by centrifugation at 400g
for 15minutes. Plasmawas removed and centrifuged at 1500g for 10minutes at
room temperature to pellet out the platelets. Platelet-poor plasma was
collected. The cell fraction was carefullymixedwith dextran (Sigma, Helsinki,
Finland) and the erythrocytes were allowed to settle for 30 minutes at room
temperature. The leukocyte fraction was collected, washed, resuspended in
platelet-poor plasma, and carefully layered atop Ficoll (GELife Sciences, Hel-
sinki, Finland) and centrifuged at 700g for 15 minutes. After FICOLL gradient
centrifugation, the PBMC layer was collected, the supernatant was removed,
and the erythrocytes in the granulocyte fractionwere lysed using a lysing buffer
containing 1 mM EDTA, 150 mM NH4CL, and 10 mM NaHCO3 in water for
3 minutes followed by centrifugation at 483g for 8 minutes at room tempera-
ture. Cells were washed twice using 0.9% NaCl. Cells were then resuspended
in HBSS (Thermo Scientific) medium until use. Trypan blue exclusion assay
was used to assess the viability of the isolated granulocytes.
Approximately 106 granulocytes from patient and 2 healthy controls were
fixed with 2-fold strength fixative in 1:1 ratio to give final concentration of
2.5% glutaraldehyde (Sigma) in 0.1 mol natrium cacodylate buffer, pH 7.4.
After 2 hours of fixation, the cells were processed for transmission electronmi-
croscopy by osmication, dehydration in a graded ethanol series and acetone,
and infiltration gradually with Epon at room temperature. Thin sections
were imaged by transmission electron microscope (Tecnai F12; FEI Comp.)
operated at 80 kV. The images were acquired at nominal magnification of
48003 using Orius SC 1000B CCD camera (Gatan Inc, Pleasanton, Calif).
The sampling for target cells was randomized, provided that the cells had at
least 2 disguised nuclear profiles.
For estimation of the size and frequency of mitochondria from control and
patient granulocytes, mitochondria and cytoplasmic area were manually
traced in the digital images and measured using Image-Pro Analyzer 7.0
(Media Cybernetics Inc, Rockville, Md). The total cytoplasmic areas
calculated were 670, 530, and 560 mm2 for 2 control specimens and patient,
respectively.
RNA sequencing
For RNA sequencing, cultured primary fibroblasts from the studied patient
and 2 healthy controls were plated in 6-well plates at 15,000 cells/well. The
following day, the cells were mock-treated or Tunikamycin-stimulated (1 ng/
mL) for 1 hour. The RNAwas extracted with Qiagen All-Prep kit (Qiagen). All
samples were studied in biological triplicates and technical replicates.
Published STRT protocolE2 was applied using 10 ng total RNA as template
and following minor modifications. Forty-eight barcodes were used (see Table
E2); the cell capture buffer contained 0.1% Triton X-100, 800 nM T30-VN-
oligo, 2 mM deoxynucleotide (dNTP) mix, and 2 mM template-switching
oligonucleotide (TSO) without magnesium chloride. After cDNA synthesis,
all 48 cDNAs were pooled into one 2-mL tube using 10% PEG-6000 and
0.9 mol NaCl (final concentration). The purified cDNAwas first amplified us-
ing 14 cycles of PCR and later an additional 10 cycles to introduce a complete
set of adapters for Illumina single read sequencing. Ready library was size-
selected using sequential AMPure XP bead selection protocol where 0.73
and 0.223 bead/PCR product ratios were used.
After the sequencing, the reads were processed by STRTprep package
(https://github.com/shka/STRTprep; manuscript in preparation). Low-
quality reads and PCR duplicons were excluded from the analysis. The
reads were trimmed and separated by the barcodesE3 and aligned to
GRCh37/hg19 genome, human ribosomal DNA unit (GenBank: U13369)
using TopHat.E4 The expression levels were estimated by strand-specific
50-bp windows (sliding 25 bp). ERCC spike-in RNA read counts, spike-in
5’-end capture rate, endogenous polyA1RNA rate, and PC1 and PC2 scores
in Principal component analysis (PCA) plot were used for sample quality
assessment.
For differential expression tests, we selected 2 deeply sequenced
biological replicates in each comparing group, and 1 technical replica in
each biological replica was used. Then, the fluctuated regions, which had
broader coefficients of variation rather than technical variation of spike-in
RNA, were selected (P < .1 with Bonferroni correction; unpublished data).
Finally, the significance of differential expression in the fluctuated regions
was assessed by SAMstrt package.E5 Genes with reads mapping to
protein-coding RNA sequence with Q value of less than 0.1 and P value
of less than .1 were considered differentially expressed. The biological clus-
tering and pathway analysis was conducted using DAVID bioinformatics
database.
Evaluation of mitochondrial respiratory capacity
The XF Mito Stress Test Kit (Seahorse Bioscience, North Billerica,
Mass) was used to evaluate the basal and maximal mitochondrial respiration
and the cellular ATP production. The patient and healthy control (n 5 3)
primary skin fibroblasts were seeded to XF cell culture microplates at a
density of 30,000 cells/well (12 technical replicates per case) and incubated
overnight at 378C in normal medium (RPMI supplemented with 20% FBS,
1% L-glutamine, and 1% Penicillin-Streptomycin). The next day, the media
was replaced with assay medium (XF base medium supplemented with
5 mM pyruvate, 5 mM glutamine, and 10 mM glucose) and cells incubated
in a non-CO2 incubator for 1 hour at 378C. The plate was then loaded into
the XFe96 Extracellular Flux Analyzer (Seahorse Bioscience) and measure-
ments were carried out according to the XF Mito Stress Test Kit protocol.
The resulting data were analyzed with the XFAnalyzer/Wave software (Sea-
horse Bioscience).
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FIG E1. A, Sanger sequencing of the HYOU1 mutants in index patient and her parents. B, HYOU1 protein
expression and subcellular localization (C) in Flp-In 293 T-REx cells. Both mutants are expressed equally,
and the subcellular localization is unaltered. DAPI, 49-6-diamidino-2-phenylindole, dihydrochloride;
HA, Hemaggluting tag.
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FIG E2. Some of the ectopic interaction partners of the mutant HYOU1
proteins were upregulated on the RNA sequencing of patient primary
fibroblasts. Genes with statistically significant differential expression
(P < .05) are shown. NME2, Nucleoside diphosphate kinase B; PTMA, pro-
thymosin alpha; PTMS, parathymosin; TPI1, triosephosphate isomerase 1.
J ALLERGY CLIN IMMUNOL
APRIL 2017
1391.e5 LETTERS TO THE EDITOR
FIG E3. A, Significantly altered metabolites in primary fibroblasts. B,Mitochondrial respiration capacity on
patient and healthy control primary fibroblasts. The patient cells perform on low normal range, but no sta-
tistically significant abnormality is evident. Time points between 0 and 20minutes evaluate basal mitochon-
drial respiration, 20 to 50 minutes cellular ATP production, and 50 to 80 minutes the maximal respiratory
capacity. OCR, Oxygen consumption rate.
J ALLERGY CLIN IMMUNOL
VOLUME 139, NUMBER 4
LETTERS TO THE EDITOR 1391.e6
TABLE E1. Immunological features of the patient
Immunologic feature
Normal range/
healthy control
median value Patient
Leukocytes 3,400-8,200 3500
Lymphocytes 1,000-4,500 910 Y
Monocytes 200-800 350
Neutrophils 1,500-7,500 150-4000 Y
Basophils 0-100 0-10 Y
Eosinophils 100-400 0 Y
Platelets 150,000-360,000 342000
NK cells (CD32CD161/561) 90-600 306
Dendritic cells
Plasmacytoid lin2HLA-DR1CD1231CD11c2 0.1%-0.3% 0.05% Y
Monocytoid lin2HLA-DR1CD1232CD11c1 0.1%-0.3% 0.02% Y
CD31 T cells 700-2,100 (71%) 694 (78%)
TCRab1 0.94 1
TCRgd 1 0.06 <0.1%
CD42CD82 TCRab1 <1% 2.5% [
CD31CD41 T cells 458-1,400 (51%) 454 (66%)
CD45RO1 51% —
CD45RA1 47% 82.8% [
TCM CCR71CD45RA2 38% 12.5% Y
Naive CCR71CD45RA1 45% 74.7% [
TEM CCR72CD45RA2 11% 6.7%
Temra CCR72CD45RA1 4% 3.1%
Granzyme B1 1% 1%
Unstimulated IFN-g/TNF-a secretion 0% 0.7%
Stimulated* IFN-g/TNF-a secretion 5% 7.7%
Treg cell FOXP31CD251 2.3%-7.8% 0.23% Y
Suppressive capacity Normal
TH17 CD69
1IL171 1.41%
CD31CD81 T cells 200-1200 243 (33%)
CD45RO1 41% —
CD45RA1 72% 95.3% [
TCM CCR71CD45RA2 8% 0.6% Y
Naive CCR71CD45RA1 35% 72% [
TEM CCR72CD45RA2 27% 2.9% Y
Temra CCR72CD45RA1 33% 24.3% Y
Granzyme B1 11% 12.5%
Unstimulated IFN-g/TNF-a secretion 0% 1.2% [
Stimulated* IFN-g/TNF-a secretion 7.20% 7.6%
CD191 B cells 70-230 8 Y
Transitional CD38hiIgMhi 0.6%-3.5% 0%
Naive CD272IgD1 — 10%
Mature B cells CD211 11%-45% 94% [
Memory CD271 15%-45% 73% [
Marginal zone-like CD271IgD1IgM1 7.2%-30.8% 57%
Switched memory CD271IgD2IgM2 6.5%-29.2% 0.04% Y
Plasmablasts CD3811IgM2 — 0
Activated CD38lowCD21low 0.6%-3.5% 7%
Immunoglobulins (prior IVIG)
IgG 6.8-15.0 g/L 8.0
IgA 0.52-4.02 g/L 2.79
IgM 0.47-2.84 g/L 1.69
IgE 0-110 IU/L 13
Neutrophil C5a and FMLP-induced chemotaxis Severely reduced
Neutrophil CD11b expression after stimulation (% of normal) 87%
Neutrophil ROS generation (% of normal) 170% [
Neutrophil CD66a expression 19.6% 146% [
Neutrophil CD66a expression after LPS stimulation 55.5% 90.6% [
Complement Classical, Alternative, MBL Normal
(Continued)
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TABLE E1. (Continued)
Immunologic feature
Normal range/
healthy control
median value Patient
Lymphocyte proliferative responses to
mitogens
PHA, concanavalin A, tuberculin (PPD),
pokeweed mitogen
PHA weak, concanavalin A weak,
PPD weak, pokeweed mitogen normal
Specific antibodies against vaccine antigens Antitetanus, antidiphtheria, antipneumococcal
polysaccharide
Tetanus weak, Pneumococcal undetectable
CD31 T-cell, CD41 cell, CD81 cell, and CD191 cell numbers are indicated as absolute counts (cells/mm3) and relative percentages of parent population (%). Control values are
indicated either as absolute count ranges or as medians from 3 healthy controls (%).
FMLP, Formyl-methionyl-leucyl-phenylalanine; IVIG, intravenous immunoglobulin therapy; MBL, Mannan-binding lectin pathway; NK, natural killer; PPD, purified protein
derivative; ROS, reactive oxygen species; TCM, central memory T cell; TEM, effector memory T cell; Temra, effector memory RA T cell.
*Stimulated with anti-CD3, anti-CD28.
Data obtained before rituximab therapy.
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TABLE E2. Analysis of monocyte and dendritic cell activation
(fluorescence intensity shown as arbitrary units)
Mitogen (dilutions) % of control
PHA (1:50, 1:200, 1:500) 23%, 36%, 32%
Concanavalin A (1:50, 1:200, 1:500) 24%, 66%, 17%
Pokeweed mitogen (1:100) 82%
Tuberculin purified protein derivative (PPD) 0%
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TABLE E3. Lymphocyte proliferative responses to mitogens
Marker
lin2HLA-DR1CD1231 dendritic cells CD141 monocytes
Healthy control median (n 5 3) Patient Healthy control median (n 5 3) Patient
CD861 15 7.47 Y 19.8 8.32 Y
LPS1 CD861 27.1 19.6 42.9 14.6 Y
PolyI:c CD861 7.08 NA 27.8 NA
CD801 6.29 7.66 12.8 13.6
LPS1 CD801 7.61 10.6 27.1 21.9
PolyI:c CD801 12.8 NA 6.85 NA
a41 451 614 160 42.9 Y
LPS1 a41 310 703 209 50.5 Y
PolyI:c a41 121 NA 106 43.5 Y
b71 167 218 114 24.2 Y
LPS1 b71 131 211 148 37.6 Y
PolyI:c b71 60 26.3 64.4 17.2 Y
CCR91 77.1 10.6 Y 61.8 38.5 Y
LPS1 CCR91 158 10.1 Y 98.9 48 Y
PolyI:c CCR91 14.55 12.1 68.6 38.8 Y
CCR21 27.7 45.4 [ 81.3 80.3
LPS1 CCR21 33.5 58.5 [ 97.8 79.9
PolyI:c CCR21 32.8 29 69.05 81.7
NA, Not applicable/available.
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TABLE E4. Genetic causes of congenital neutropenia*
Gene ELANE HAX1 VPS45 JAGN1 G6P3 HYOU1 LAMTOR2 AP3B1 RAB27A
Clinical characteristics
Inheritance AR, AD AR AR AR AR AR AR AR AR
Infection
susceptibility
Bacteria Bacteria Bacteria Bacteria Bacteria Bacteria, herpesvirus Bacteria Bacteria Bacteria
Immunology Neutropenia,
cyclic
neutropenia
Neutropenia Neutropenia,
hypergammaglob
ulinemia,
myelofibrosis
Neutropenia Neutropenia,
thrombocytopenia
Granulocytopenia,
thrombocytopenia,
anemia, B-cell
deficiency, dendritic
cell deficiency
Neutropenia,
hypogammaglobuli
nemia
Granulocytopenia,
coagulation
defects,
decreased
NK and T-cell
cytotoxicity
Neutropenia,
decreased
NK and T-cell
cytotoxicity
Other features — Neurological
impairment
(some cases)
Hepato-, spleno-,
& nephromegaly
(extramedullary
hematopoiesis)
Bone and
dental
anomalies
Syndromic patients Hypoglycemia, mild bone
anomalies
Oculocutaneous
albinism
Oculocutaneous
albinism
Oculocutaneous
albinism
Malignancy
predisposition
1 1 1 2 2 2 2 2 2
Molecular pathogenesis
Cellular
compartment
ER Mitochondria ER, vesicular
system
ER ER ER, mitochondria Vesicular
transport
system
Vesicular
transport
system
Vesicular
transport
system
Pathogenic
mechanism
ELANE
accumulation
in the ER,
UPR induction,
& neutrophil
apoptosis
Mitochondrial
destabilization,
disturbed stress
signaling
-> neutrophil
apoptosis
Defective
endosomal
trafficking
Protein
accumulation
in the ER,
defective
glycosylation,
UPR induction
-> neutrophil
apoptosis
Impaired ER
glucose
metabolism
and protein
glycosylation
-> UPR &
neutrophil
apoptosis
Altered UPR and redox
balance
Impaired
vesicular
transport
Impaired
vesicular
transport
Impaired
vesicular
transport
The clinical and molecular characteristics of HYOU1 deficiency have been italicized and underlined.
AR, Autosomal recessive; AD, autosomal dominant; ER, endoplasmic reticulum; UPR, unfolded protein response.
*Genes with function in cell stress pathways or in the endolysosomal system are shown.E6,E7
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